Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Long-term treatment outcomes of patients with primary optic nerve sheath meningioma treated with stereotactic radiotherapy

Ratnayake G, Oh T, Mehta R, Hardy T, Woodford K, Haward R, Ruben JD, Dally MJ

(2019), J Clin Neurosci, 68, 162-7

DOI: 10.1016/j.jocn.2019.07.005

Body size and dietary risk factors for aggressive prostate cancer: a case-control study

Pal M, Hodge AM, Papa N, MacInnis RJ, Bassett JK, Bolton D, Davis ID, Millar J, English DR, Hopper JL, Severi G, Southey MC, Milne RL, Giles GG

(2019), CANCER CAUSE CONTROL, 30(12), 1301-12

DOI: 10.1007/s10552-019-01234-7

Contemporary practice patterns of stereotactic radiosurgery for brain metastasis: A review of published Australian literature

Ong WL, Wada M, Ruben J, Foroudi F, Millar J

(2019), J MED IMAG RADIAT ON, 63(5), 711-20

DOI: 10.1111/1754-9485.12942

Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models

Earnest A, Evans SM, Sampurno F, Millar J

(2019), BMJ Open, 9(8), e031331

DOI: 10.1136/bmjopen-2019-031331

Development of a muticentre automated model to reduce planning variability in radiotherapy of prostate cancer

Panettieri V, Ball D, Chapman A, Cristofaro N, Gawthrop J, Griffin P, Herath S, Howly S, Jukes L, Kron T, Markham C, Marr L, Moloney P, Nelli F, Ramachandran P, Smith A, Hornby CJ

(2019), Phys Imaging Radiat Oncol, 11, 39-40

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S

(2019), Lancet, 393(10185), 2051-8

DOI: 10.1016/S0140-6736(18)32487-5

Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings

Beckmann K, O'Callaghan M, Vincent A, Cohen P, Borg M, Roder D, Evans S, Millar J, Moretti K

(2019), Asian J Urol, 6(4), 321-9

DOI: 10.1016/j.ajur.2019.03.001

Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry

Sampurno F, Kannan A, Lucas M, Liman J, Connor SE, Pearman E, Millar JL, Moore CM, Villanti P, James E, Huland H, Litwin MS, Evans SM

(2019), JCO Clin Can Inform, 3, 1-11

DOI: 10.1200/CCI.18.00114

Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone

Kent AR, Matheson B, Millar JL

(2019), Brachytherapy, 18(3), 313-21

DOI: 10.1016/j.brachy.2019.01.013

A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03)

Wirth A, Prince HM, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone JM, Davis S, Hertzberg M

(2019), INT J RADIAT ONCOL, 103(5), 1158-66

DOI: 10.1016/j.ijrobp.2018.12.006

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

Wong Doo N, White VM, Martin K, Bassett JK, Prince HM, Harrison SJ, Jefford M, Winship I, Millar JL, Milne RL, Seymour JF, Giles GG

(2019), Cancers, 11(7), 928

DOI: 10.3390/cancers11070928

Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape

Philip J, Collins A, Ritchie D, Le B, Millar J, McLachlan SA, Krishnasamy M, Hudson P, Sundararajan V

(2019), LEUKEMIA LYMPHOMA, 60(8), 1908-16

DOI: 10.1080/10428194.2018.1564047

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B; TROG 09.02 CHISEL investigators

(2019), Lancet Oncol, 20(4), 494-503

DOI: 10.1016/S1470-2045(18)30896-9

Fractionated Stereotactic Radiotherapy for Cavernous Venous Malformations of the Orbital Apex

Ratnayake GS, McNab AA, Dally MJ, Zajarski C, Senthi S, Ruben JD

(2019), OPHTHAL PLAST RECONS, 35(4), 322-5

DOI: 10.1097/IOP.0000000000001239

Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria

Ong WL, Foroudi F, Evans S, Millar J

(2019), J MED IMAG RADIAT ON, 61(1), 124-30

DOI: 10.1111/1754-9485.12818

The trajectory of patients who die from metastatic prostate cancer: a population-based study

Collins A, Sundararajan V, Millar J, Burchell J, Le B, Krishnasamy M, McLachlan SA, Hudson P, Mileshkin L, Philip J

(2019), BJU Int, 123 Suppl 5, 19-26

DOI: 10.1111/bju.14593

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, S Karapetis C, Price T, Schaefer MJ, Ptak J, Dobbyn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P

(2019), Gut, 68(4), 663-71

DOI: 10.1136/gutjnl-2017-315852

Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy

Beckman K, O'Callaghan M, Vincent A, Roder D, Millar J, Evans S, McNeil J, Moretti K

(2018), ANZ J Surg, 88(3), e183-188

DOI: 10.1111/ans.13954

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method

Tsiamis E, Millar J, Baxi S, Borg M, De Ieso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S

(2018), Radiother Oncol, 128(2), 308-14

DOI: 10.1016/j.radonc.2018.04.017

An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging

Smith RL, Hanlon M, Panettieri V, Millar JL, Matheson B, Haworth A, Franich RD

(2018), Brachytherapy, 17(1), 111-121

DOI: 10.1016/j.brachy.2017.08.004

2 3 4 5 6